Melkersson-Rosenthal syndrome (MRS) is a rare neuro-mucocutaneous systemic disease that is characterized by relapsing peripheral facial paralysis, orofacial edema and fissured tongue. The classical complete triad is present in about 25% of cases, whereas the mono or oligo-symptomatic forms are more common and include the so-called cheilitis granulomatosa. The orofacial edema is the dominant finding and may be the presenting sign in 42% of cases. MRS equally affects individuals of each sex in the second decade of life and its course is usually chronic but benign (1) . The typical histological finding of MRS is represented by noncaseating epitheloid cell granulomas characterized by aggregates of histiocytes, plasma cells, lymphocytes and Langhans giant cells. Recent studies have considered MRS a granulomatous disease and an association between the orofacial symptoms of MRS and Crohn's disease has been suggested, based on the histological similarity between the two conditions (2) .
However, in the early stages of disease the typical granuloma is not always detected as the histological alterations are represented by perivascular inflammatory infiltrates with histiocytes, lymphocytes and plasma cells with or without granuloma formation (3) (4) . These features can be difficult to find, but their absence does not exclude the diagnosis of MRS. The disease etiology is still not well known, but it has been hypothesized that a possible role is played by various causal agents, such as infectious diseases, genetic causes, allergic conditions, benign lymphogranulomatosis, various associations with other pathological conditions, particularly with immune-mediated diseases and food contact allergies (5, 6) . We report the case of a 42-year-old woman with psoriatic arthritis who developed neurological episodes related to MRS after treatment with anti-tumor necrosis factor (TNF) therapy.
Case report
A 42-year-old Caucasian woman suffering from swelling and pain in the proximal interphalangeal joints of the hands, in the ankles and the right knee was admitted to our outpatient clinic. On clinical examination, asymmetrical arthritis involving the metacarpo-phalangeal, the inter-phalangelal joints, both ankles and the left knee was observed. Furthermore, the presence of reddish skin and a scaly rash located over the surfaces of the elbows and in the ears that was attributable to psoriatic lesions, was noted, together with nail involvement (nail pitting and subungual hyperkeratosis). Laboratory blood tests including the Waaler Rose, RA Test, antinuclear factor and angiotensin converting enzyme were negative. Renal and liver function tests, a full blood cell count and urinalysis were normal. The HLA-B27 antigen was absent. A chest X-ray was performed and was normal. Radiographs of the hands showed joint space narrowing of proximal and distal interphalangeal joints of both hands, with asymmetrical distribution, the fusion of the left sacroiliac joint and the presence of bilateral dorsal and plantar calcaneal enthesitis. Psoriatic arthritis was diagnosed and the patient was started on a treatment with methotrexate (15 mg/week) and a NSAID. Owing to a lack of efficacy over 7 months of therapy, etanercept (50 mg/wk) was added to methotrexate. After one year of etanercept treatment, the patient developed progressive weakness, paresthesia and dysaesthesia (burning sensation) of the right side of the face, hypogeusia, dysphonia and dysphagia for solids. On clinical examination, a minimal strength deficit and sensitivity of the right side of the face was present, together with non-painful, erythematous swelling both on the right side of the face and the lower and upper lips. These symptoms were preceded by neck pain and a reduction in vision. Vision-evoked potentials, brain and spine nuclear magnetic resonance imaging, electroneurography and electromyography ofthe upper and lower limbs, and cerebrospinal fluid analysis were normal. Neck ultrasonography revealed the presence of laterocervical enlarged lymphnodes. A biopsy of the lower lip mucosa was performed, the histological examination of which revealed the presence of perivascular infiltrates of lymphocytes, plasma cells and histiocytes associated with multiple non-necrotic granulomas with Langhans giant cells. When the etanercept therapy was discontinued, the patient showed a slow improvement of neurological symptoms, in spite of the persistence of a minimal residual swelling of the upper lip. DISCUSSION MRS is a rare systemic disease clinically characterized by recurrent facial paralysis, recurrent or persistent swelling of the orofacial tissues and other various orofacial symptoms such as fissured tongue. Monosymptomatic or oligoasymptomatic forms of this disease have been described (1, 3) . Other neurologic manifestations have been reported, such as hypoacusia, acroparesthesia, blepharospasm and dysphagia.
The typical pathological findings of MRS are represented by the presence of noncaseating epithelioid cell granulomas, multinucleated Langhans-type giant cells, perivascular mononuclear inflammatory infiltration, lymphoedema and fibrosis. The etiology and pathogenesis of MRS are still unclear, but various hypotheses have been proposed such as allergic reactions, a vasomotor disorder of the vasa vasorum, infectious processes and autoimmune dysregulation. The hypothesis ofan autoimmune involvement in the pathogenesis of this disease has been suggested by its association with other autoimmune diseases, such as autoimmune thyroiditis and multiple sclerosis (7, 8) as reported in the literature. Furthermore, the characteristic finding of non-necrotic granuloma places MRS in the same group of other granulomatous diseases in which an autommune dysregulation is involved, such as sarcoidosis and Crohn's disease (3, 4, 9-11). The association between MRS and psoriatic arthritis could further support the hypothesis of an autoimmune pathogenesis ofthis syndrome; however, the temporal evolution of clinical manifestations characterized by the onset of disease after the introduction of etanercept treatment and the improvement of symptoms after treatment discontinuation, strongly suggests a possible triggering role of anti-TNF-a therapy in the development of MRS.
TNF-a is a proinflammatory cytokine produced primarily by monocytes, macrophages and T cells in response to various exogenous and endogenous signals. It plays a significant role in antigenstimulated, cell-mediated immune responses and it is essential for the formation and maintenance of granulomas in a large variety of diseases, such as sarcoidosis and tuberculosis (12) . In sarcoidosis alveolar macrophage-derived TNF-a participates in the induction and maintenance of granulomas, processes that include endothelial cell activation, induction of adhesion molecules, growth of new blood vessels and regulation of other inflammatory cytokines (13) . In fact, it is well established that the use of anti-TNF drugs for the treatment of various chronic inflammatory conditions, such as rheumatoid arthritis, is associated with the reactivation of granulomatous infections due to the reduced ability of immune cells to maintain the granuloma structure (14) . However, a paradoxical effect of TNF inhibition, regarding the development and maintenance of granuloma lesions, has been shown by various reports and case series (15, 16) , and certain granulomatous syndromes have been described in patients receiving anti-TNF-a therapy (17) , such as in sarcoidosis and Crohn's disease, interstitial granulomatous dermatitis (18) , giant cell arteritis (19) . Even rare cases of rheumatoid nodules of the lungs have been described in patients with rheumatoid arthritis receiving anti-TNF-a treatment (20) (21) (22) .
Furthermore, it is interesting to note that in Crohn's disease the treatment with infliximab (a murine-human chimeric anti TNF monoclonal antibody that binds monomeric and trimeric TNF) is useful and officially approved, whereas the treatment with etanercept (a fusion molecule of the extracellular portion ofthe TNF receptor linked to the Fc domains of human IgG1) is not only ineffective, but often causes a disease reactivation. Some cases of Crohn's disease have been reported in patients with ankylosing spondylitis taking anti-TNF agents (23) , and recently it has been confirmed that paradoxical inflammatory bowel diseases may occur during anti TNF-a therapy for inflammatory rheumatic disease, mostly in patients with spondylarthropathies while receiving etanercept (17) . In addition, in an openlabel study, it has been observed that etanercept used in progressive pulmonary sarcoidosis induced a worsening of the disease in the majority of patients, while many cases of successful treatment with infliximab have been reported (24) . Thus, a wide range of sarcoid-like granulomatous reactions has been observed in patients taking anti-TNF for chronic inflammatory disease, and these reactions have been more frequently reported with the TNF-a soluble receptor rather than with monoclonal anti-TNF-a antibodies. These opposite effects between TNF-a blockers of inducing granulomatous lesions could be due to the different biological properties of etanercept compared to the other anti-TNF agents infliximab and adalimumab. The soluble receptor etanercept neutralizes soluble TNF-a and binds to membrane TNF-a with reduced avidity compared to infliximab; etanercept has different binding avidities and different clearance; infliximab inhibits both the p55 and p75 TNF-a receptor while p75 is only partially inhibited by etanercept (25) ; infliximab induces apoptosis in memory T cells, whereas etanercept is anti-apoptotic; above all, infliximab inhibits TNF-a expression (that plays an essential role in granuloma formation) while etanercept can enhance T-cell production of TNF-a, and may contribute in particular conditions to the occurrence of sarcoid-like granulomatosis (26) . However, the appearance of some granulomatous diseases has been reported with anti-TNF-a drugs other than etanercept, and this suggests that anti-TNF-a treatment could precipitate the development of granulomas in predisposed patients.
To our knowledge, we described the first case of MRS in a patient receiving anti-TNF-a treatment for chronic inflammatory joint disease; this is a rare granulomatous disease, but further supports the hypothesis that TNF-a blockade, and particularly the use of the TNF-a receptor could trigger, in predisposed patients, the development of granulomatous lesions. To date, the exact mechanisms underlying the development of noninfectious granulomatous diseases by use of TNF-a drugs are not well understood, but the case we report further sustains the importance of the clinician to take into account this potential adverse event in patients receiving anti-TNF-a therapies.
